DOCSLIB.ORG

Use of High Dose Cyproterone Acetate and Risk of Intracranial Meningioma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Use of High Dose Cyproterone Acetate and Risk of Intracranial Meningioma RESEARCH Use of high dose cyproterone acetate and risk of intracranial BMJ: first published as 10.1136/bmj.n37 on 3 February 2021. Downloaded from meningioma in women: cohort study Alain Weill,1,2 Pierre Nguyen,2,3 Moujahed Labidi,4 Benjamin Cadier,1 Thibault Passeri,4 Lise Duranteau,5 Anne-Laure Bernat,4 Isabelle Yoldjian,3 Sylvie Fontanel,6 Sébastien Froelich,4 Joël Coste1,7 1Department of Public Health ABSTRACT meningiomas in the control group (during 439 949 Studies, French National Health OBJECTIVE person years of follow-up) were treated by surgery or Insurance, Paris, France radiotherapy. The incidence of meningioma in the two 2 To assess the risk of meningioma associated with EPI-PHARE Scientific Interest groups was 23.8 and 4.5 per 100 000 person years, Group, Saint-Denis, France use of high dose cyproterone acetate, a progestogen respectively (crude relative risk 5.2, 95% confidence 3French National Agency for the indicated for clinical hyperandrogenism. interval 3.2 to 8.6; adjusted hazard ratio 6.6, 95% Safety of Medicines and Health DESIGN Products (ANSM), Saint-Denis, confidence interval 4.0 to 11.1). The adjusted Observational cohort study. France hazard ratio for a cumulative dose of cyproterone 4 Department of Neurosurgery, SETTING acetate of more than 60 g was 21.7 (10.8 to 43.5). Lariboisière Hospital, AP-HP, Data from SNDS, the French administrative healthcare University of Paris, Paris, France After discontinuation of cyproterone acetate for one database, between 2007 and 2015. 5Gynaecology Unit and Reference year, the risk of meningioma in the exposed group Center for Rare Diseases of PARTICIPANTS was 1.8-fold higher (1.0 to 3.2) than in the control Genital Development, AP-HP, 253 777 girls and women aged 7-70 years living in group. In a complementary analysis, 463 women with University Paris Saclay, Bicêtre meningioma were observed among 123 997 already Hospital, Le Kremlin-Bicêtre, France who started cyproterone acetate between France 2007 and 2014. Participants had at least one using cyproterone acetate in 2006 (risk of 383 per 6Grand Est Regional Health reimbursement for high dose cyproterone acetate 100 000 person years in the group with the highest Authority, Nancy, France and no history of meningioma or benign brain exposure in terms of cumulative dose). Meningiomas 7Biostatistics and Epidemiology tumour, or long term disease status. Participants located in the anterior skull base and middle skull Unit, Cochin Hospital, AP-HP, were considered to be exposed when they had base, particularly the medial third of the middle skull Paris, France received a cumulative dose of at least 3 g during base, involving the spheno-orbital region, appeared Correspondence to: A Weill EPI-PHARE the first six months (139 222 participants) and very to be specific to cyproterone acetate. An additional Scientific Interest Group, slightly exposed (control group) when they had analysis of transgender participants showed a high http://www.bmj.com/ 42 Bd de la Libération, received a cumulative dose of less than 3 g (114 555 risk of meningioma (three per 14 460 person years; 93200 Saint-Denis, France 20.7 per 100 000 person years). [email protected] participants). 10 876 transgender participants (male (ORCID 0000-0001-8687-9092) to female) were included in an additional analysis. CONCLUSIONS Additional material is published MAIN OUTCOME MEASURE A strong dose-effect relation was observed between online only. To view please visit use of cyproterone acetate and risk of intracranial the journal online. Surgery (resection or decompression) or radiotherapy for one or more intracranial meningiomas. meningiomas. A noticeable reduction in risk was Cite this as: BMJ 2021;372:n37 observed after discontinuation of treatment. http://dx.doi.org/10.1136/bmj.n37 RESULTS on 1 October 2021 by guest. Protected copyright. Accepted: 3 December 2020 Overall, 69 meningiomas in the exposed group (during 289 544 person years of follow-up) and 20 Introduction Cyproterone acetate is a synthetic progestogen with a potent antiandrogen action. The drug has WHAT IS ALREADY KNOWN ON THIS TOPIC been approved in European countries by national Cyproterone acetate is a synthetic progestogen with strong antiandrogen and marketing authorisation procedures since the 1970s and is available on prescription under various trade antigonadotrophin effects names and dose strengths (1, 2, 10, 50, and 100 Since 2007, several case series of intracranial meningiomas have described mg). The indications for cyproterone acetate also vary patients who developed one or more meningiomas after using cyproterone considerably from one country to another. Cyproterone acetate at doses of 25-100 mg daily for 5-30 years acetate is indicated in men (50 or 100 mg) with The presence of progesterone receptors on meningiomas supports the biological inoperable prostate cancer and paraphilias. In women, plausibility of an association the 50 mg dose is indicated for various disorders WHAT THIS STUDY ADDS of the hirsutism or hyperandrogenism spectrum in 19 European countries, including France, Spain, This study confirms a strong and dose dependent association between use Germany, Belgium, Poland, and the Netherlands. In of high dose cyproterone acetate (25 or 50 mg/day) in girls and women and other European countries, 10 mg tablets are marketed meningioma treated by surgery or radiotherapy and indicated for signs of androgenisation and certain The risk of meningioma in the group who used cyproterone acetate for 10-30 forms of hirsutism (table 1 shows approved indications years was four participants per 1000 person years in women in Europe; supplementary material S1 Meningiomas located in the anterior skull base and middle skull base appeared shows approved indications in men in Europe). to be specific to cyproterone acetate; the risk decreased after cyproterone Cyproterone acetate is also used at a low dose of 2 mg acetate was discontinued combined with 35 µg ethinylestradiol for the treatment the bmj | BMJ 2021;372:n37 | doi: 10.1136/bmj.n37 1 RESEARCH of acne related to androgen sensitivity or hirsutism in incidence of treated meningioma (event of interest) in women of reproductive age, and at a dose of 1 mg in girls and women (age 7-70 years) who used high dose BMJ: first published as 10.1136/bmj.n37 on 3 February 2021. Downloaded from combination with estradiol valerate 2 mg as hormone cyproterone acetate with the incidence in those who replacement therapy. prematurely discontinued cyproterone acetate and Since 2007, several case series of both men and were only very slightly exposed (control group). women have reported meningioma associated with The main study included a cohort of women who prolonged use (5-30 years) of high dose cyproterone started high dose cyproterone acetate between 2007 acetate (25-100 mg daily).1-11 The labelling of and 2014, with follow-up to the end of 2015. Under cyproterone acetate (10, 50, and 100 mg) was modified optimal epidemiological conditions (new incident in 2009,12 and since 2011 and 2013 the labelling users with known cumulative doses over time), we of both the brand name drug and generic drugs, tested the hypothesis of an association between respectively, indicate that meningiomas have been exposure and risk of meningioma, and evaluated a reported in people with prolonged use of cyproterone possible dose-effect relation. acetate.13 A history or presence of meningioma We also analysed a population of girls and women now also constitutes a contraindication to use of who were already using cyproterone acetate in 2006, cyproterone acetate.12 13 and followed this cohort until the end of 2015. Based Two low powered epidemiological studies on the on the hypothesis of a causal association, we used this link between cyproterone acetate and meningioma population to define the characteristics of cyproterone have been published. One of the studies reported two acetate related meningiomas and the number of men and two women with meningioma, corresponding meningiomas treated by surgery or radiotherapy that to a relative risk of 11.4 (95% confidence interval 4.3 were attributable to cyproterone acetate use. This to 30.8).14 The other study found an excess risk in men cohort comprised women who had continually used (four men with meningioma) with an odds ratio of 3.3 cyproterone acetate for a long period (more than (1.0 to 10.6), but concluded that low dose cyproterone eight years), although left censoring of data occurred acetate was not associated with an increased risk of because only cumulative doses since 2006 are known meningioma in women.15 with certainty. We conducted a further analysis on We evaluated the real life impact of prolonged use of a population of transgender participants (male to high dose cyproterone acetate on risk of meningioma female) who started high dose cyproterone acetate in girls and women. Our secondary objectives were between 2007 and 2017, with follow-up until the end to evaluate the dose-effect relation, define the course of 2018. http://www.bmj.com/ of the risk of meningioma after discontinuation of cyproterone acetate, identify specific features of Data source cyproterone acetate related meningiomas, measure SNDS covers the entire population of France—67 the effective discontinuation rate for cyproterone million residents. Each person is identified by a acetate after treatment for meningioma, and estimate unique, anonymous number. Since 2006, SNDS has the number of meningiomas treated by surgery recorded information on all outpatient care (including or radiotherapy that were attributable to use of drugs, imaging, and laboratory tests) and inpatient cyproterone acetate in France. In an additional care (including diagnoses and procedures performed, on 1 October 2021 by guest. Protected copyright. analysis, we evaluated the real life impact of prolonged coded according to the common classification of use of high dose cyproterone acetate on risk of medical procedures—CCAM).
Load more

Recommended publications
  • "Macrolides"? Classify Each Drug in This Chapter As a Macrolide Or Azalide, and As an Antibiotic Or Semi-Synthetic Derivative
    STUDY GUIDE THE MACROLIDE/AZALIDE ANTIMICROBIAL AGENTS 1. Why are these antibiotics derivatives called "macrolides"? Classify each drug in this chapter as a macrolide or azalide, and as an antibiotic or semi-synthetic derivative. 2. What are the key structural differences between erythromycin, clarithromycin, azithromycin and dirithromycin? 3. Generally how does spiramycin and josamycin differ in structure from the commercial macrolides/azalides (2 reasons)? 4. What are the “ketolides and how do they differ in structure from the commercial macrolides? 5. What is the biosynthetic source of erythromycin? What is the lactone moiety of erythromycin called? What sugar moieties are present and what are their properties? 6. What hydrolysis product forms from erythromycin in aqueous acid or base? What is the significance of this reaction? Can it occur with other macrolides? 7. When does the “intramolecular cyclization” reaction occur with erythromycin? What is it's significance (two reasons) and how does it occur? Which functional groups are important for this reaction? 8. What salt forms of erythromycin are available? Which are water soluble? Which are water-insoluble? How is each salt form formulated and used (oral or parenteral)? 9. What ester and ester salt derivatives of erythromycin are available? What is the estolate? How is each salt form formulated and used (oral or parenteral)? What are the advantages of these esters dosage forms? 10. How does clarithromycin differ in structure from erythromycin? Why was this macrolide developed (the role of the 6-methoxy)? 11. How does azithromycin differ in structure from erythromycin? Why was this macrolide developed? 12. How does dirithromycin differ in structure from erythromycin? Why was this macrolide developed? What is the active form of this prodrug? 13.
    [Show full text]
  • 35 Cyproterone Acetate and Ethinyl Estradiol Tablets 2 Mg/0
    PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PrCYESTRA®-35 cyproterone acetate and ethinyl estradiol tablets 2 mg/0.035 mg THERAPEUTIC CLASSIFICATION Acne Therapy Paladin Labs Inc. Date of Preparation: 100 Alexis Nihon Blvd, Suite 600 January 17, 2019 St-Laurent, Quebec H4M 2P2 Version: 6.0 Control # 223341 _____________________________________________________________________________________________ CYESTRA-35 Product Monograph Page 1 of 48 Table of Contents PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 3 SUMMARY PRODUCT INFORMATION ............................................................................................. 3 INDICATION AND CLINICAL USE ..................................................................................................... 3 CONTRAINDICATIONS ........................................................................................................................ 3 WARNINGS AND PRECAUTIONS ....................................................................................................... 4 ADVERSE REACTIONS ....................................................................................................................... 13 DRUG INTERACTIONS ....................................................................................................................... 16 DOSAGE AND ADMINISTRATION ................................................................................................ 20 OVERDOSAGE ....................................................................................................................................
    [Show full text]
  • The Progestogen Only Pill
    The Progestogen Only Pill Mini-pill or POP A service provided by page 2 of 8 How does the progestogen only pill (POP) work? The progestogen only pill mainly works by thickening the mucus you produce from your cervix. This makes it more difficult for sperm to get to the egg. It can also sometimes stop your ovaries from producing an egg (ovulation). How effective is the pill? The effectiveness of the pill depends on the woman taking it. At best it is over 98% effective (when no pills are missed). However failure rates can be much higher (9-15%) if women do not remember to take their pill properly. Missed pills can lead to pregnancy. Advantages of the POP • It doesn’t interfere with sex. • You can use it whilst you are breastfeeding. • It is useful if you cannot take oestrogen (the hormone contained in the combined oral contraceptive) • Can be used at any age even if you smoke and are over 35 years of age. • It may help with premenstrual symptoms and painful periods. page 3 of 8 Disadvantages of the POP • You have to remember to take your pill at the same time every day. • Your periods may become irregular or even stop altogether on the POP, this is not dangerous but if you miss a period you need to check that you are not pregnant by coming to clinic for a pregnancy test. • You may get some temporary side effects, such as spotty skin, breast tenderness and mood changes, though these should stop within a few months.
    [Show full text]
  • Erythromycin Versus Tetracycline for Treatment of Mediterranean Spotted Fever
    Arch Dis Child: first published as 10.1136/adc.61.10.1027 on 1 October 1986. Downloaded from Archives of Disease in Childhood, 1986, 61, 1027-1029 Erythromycin versus tetracycline for treatment of Mediterranean spotted fever T MUNOZ-ESPIN, P LOPEZ-PARtS, E ESPEJO-ARENAS, B FONT-CREUS, I MARTINEZ- VILA, J TRAVERIA-CASANOVA, F SEGURA-PORTA, AND F BELLA-CUETO Hospital de Sant Llatzer, Terrassa, Clinica Infantil del Nen Jesus, Sabadell, and Hospital Mare de Deu de la Salut, Sabadell, Barcelona, Spain SUMMARY Eighty one children aged between 1 and 13 years participated in a randomised comparative trial of tetracycline hydrochloride and erythromycin stearate for treatment of Mediterranean spotted fever. Both therapeutic regimens proved effective, but in patients treated with tetracycline both clinical symptoms and fever disappeared significantly more quickly. Likewise, when those patients who began treatment within the first 72 hours of illness are considered the febrile period had a significantly shorter duration in the group treated with tetracycline. One patient was switched to tetracycline because there was no improvement of clinical manifestations, with persistence of fever, myalgias, and prostration, after receiving eight days of treatment with erythromycin. These results suggest that tetracyclines are superior to erythromycin in the treatment of Mediterranean spotted fever. copyright. Mediterranean spotted fever is an acute infectious were not included in the trial; neither were those disease caused by Rickettsia conorii. During the
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Outpatient Acne Care Guideline
    Outpatient Acne Care Guideline Severity Mild Moderate Severe < 20 comedones or < 20-100 comedones or 15-50 > 5 cysts, >100 comedones, or inflammatory lesions inflammatory lesions >50 inflammatory lesions Initial Treatment Initial Treatment Initial Treatment Benzoyl Peroxide (BP) or Topical Combination Therapy Combination Therapy Topical Retinoid Retinoid + BP Oral antibiotic or OR + (Retinoid + Antibiotic) + BP Topical retinoid Topical Combination Therapy or + BP + Antibiotic Retinoid + (BP + Antibiotic) or OR BP Retinoid + BP Oral antibiotic + topical retinoid + +/- or BP Topical antibiotic Retinoid + Antibiotic + BP or Topical Dapsone IF Inadequate Response IF Inadequate Response IF Inadequate Consider dermatology Response referral Change topical retinoid Consider changing oral concentrations, type and/or antibiotic formulation AND or Add BP or retinoid, if not already Change topiocal combination Consider isotretinoin prescribed therapy Consider hormone therapy or and/or (females) Change topical retinoid Add or change oral antibiotic concentrations, type and/or or formulation Consider isotretinoin Additional Considerations or Consider hormone therapy (females) Change topical comination Previous treatment/history Side effects therapy Costs Psychosocial impact Vehicle selection Active scarring Ease of use Regimen complexity Approved Evidence Based Medicine Committee 1-18-17 Reassess the appropriateness of Care Guidelines as condition changes. This guideline is a tool to aid clinical decision making. It is not a standard of care. The physician should deviate from the guideline when clinical judgment so indicates. GOAL: Pediatricians should initiate treatment for cases of “Mild” to “Severe” acne (see algorithms attached). Pediatricians should also counsel patients in order to maximize adherence to acne treatment regimens: 1. Realistic expectations. Patients should be counseled that topical therapies typically take up to 6-8 weeks to start seeing results.
    [Show full text]
  • MIRENA Data Sheet Vx3.0, CCDS 25 1
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME MIRENA 52 mg intrauterine contraceptive device (release rate: 20 microgram/24 hours) 2. QUALITATIVE AND QUANTITATIVE COMPOSITION MIRENA is an intrauterine system (IUS) containing 52 mg levonorgestrel. For details of release rates, see Section 5.2. For the full list of excipients, see Section 6.1. 3. PHARMACEUTICAL FORM MIRENA consists of a white or almost white drug core covered with an opaque membrane, which is mounted on the vertical stem of a T-body. The vertical stem of the levonorgestrel intrauterine system is loaded in the insertion tube at the tip of the inserter. Inserter components are an insertion tube, plunger, flange, body and slider. The white T-body has a loop at one end of the vertical stem and two horizontal arms at the other end. Brown coloured removal threads are attached to the loop. The T-body of MIRENA contains barium sulfate, which makes it visible in X-ray examination. The IUS and inserter are essentially free from visible impurities. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Contraception Treatment of idiopathic menorrhagia provided there is no underlying pathology. Prevention of endometrial hyperplasia during estrogen replacement therapy MIRENA Data Sheet Vx3.0, CCDS 25 1 4.2 Dose and method of administration MIRENA is inserted into the uterine cavity. One administration is effective for five years. The in vivo dissolution rate is approximately 20 microgram/24 hours initially and is reduced to approximately 18 microgram/24 hours after 1 year and to 10 microgram/24 hours after five years. The mean dissolution rate of levonorgestrel is about 15 microgram /24 hours over the time up to five years.
    [Show full text]
  • Supplementary Materials
    Supplementary Materials Table S1. The significant drug pairs in potential DDIs examined by the two databases. Micromedex Drugs.com List of drugs paired PK-PD Mechanism details 1. Amiodarone— PD Additive QT-interval prolongation Dronedarone 2. Amiodarone— PK CYP3A inhibition by Ketoconazole Ketoconazole 3. Ciprofloxacin— PD Additive QT-interval prolongation Dronedarone 4. Cyclosporine— PK CYP3A inhibition by Cyclosporine Dronedarone 5. Dronedarone— PK CYP3A inhibition by Erythromycin Erythromycin 6. Dronedarone— PD Additive QT-interval prolongation Flecainide 7. Dronedarone— PK CYP3A4 inhibition by Itraconazole Itraconazole 8. Dronedarone— PK Contraindication Major CYP3A inhibition by Ketoconazole Ketoconazole 9. Dronedarone— PD Additive QT-interval prolongation Procainamide PD 10. Dronedarone—Sotalol Additive QT-interval prolongation 11. Felodipine— PK CYP3A inhibition by Itraconazole Itraconazole 12. Felodipine— PK CYP3A inhibition by Ketoconazole Ketoconazole 13. Itraconazole— PK CYP3A inhibition by Itraconazole Nisoldipine 14. Ketoconazole— PK CYP3A inhibition by Ketoconazole Nisoldipine 15. Praziquantel— PK CYP induction by Rifampin Rifampin PD 1. Amikacin—Furosemide Additive or synergistic toxicity 2. Aminophylline— Decreased clearance of PK Ciprofloxacin Theophylline by Ciprofloxacin 3. Aminophylline— PK Decreased hepatic metabolism Mexiletine 4. Amiodarone— PD Additive effects on QT interval Ciprofloxacin 5. Amiodarone—Digoxin PK P-glycoprotein inhibition by Amiodarone 6. Amiodarone— PD, PK Major Major Additive effects on QT Erythromycin prolongation, CYP3A inhibition by Erythromycin 7. Amiodarone— PD, PK Flecainide Antiarrhythmic inhibition by Amiodarone, CYP2D inhibition by Amiodarone 8. Amiodarone— PK CYP3A inhibition by Itraconazole Itraconazole 9. Amiodarone— PD Antiarrhythmic inhibition by Procainamide Amiodarone 10. Amiodarone— PK CYP induction by Rifampin Rifampin PD Additive effects on refractory 11. Amiodarone—Sotalol potential 12. Amiodarone— PK CYP3A inhibition by Verapamil Verapamil 13.
    [Show full text]
  • Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut
    ■ CLINICAL REVIEW Diagnosis and Treatment of Tinea Versicolor Ronald Savin, MD New Haven, Connecticut Tinea versicolor (pityriasis versicolor) is a common imidazole, has been used for years both orally and top­ superficial fungal infection of the stratum corneum. ically with great success, although it has not been Caused by the fungus Malassezia furfur, this chronical­ approved by the Food and Drug Administration for the ly recurring disease is most prevalent in the tropics but indication of tinea versicolor. Newer derivatives, such is also common in temperate climates. Treatments are as fluconazole and itraconazole, have recently been available and cure rates are high, although recurrences introduced. Side effects associated with these triazoles are common. Traditional topical agents such as seleni­ tend to be minor and low in incidence. Except for keto­ um sulfide are effective, but recurrence following treat­ conazole, oral antifungals carry a low risk of hepato- ment with these agents is likely and often rapid. toxicity. Currently, therapeutic interest is focused on synthetic Key Words: Tinea versicolor; pityriasis versicolor; anti­ “-azole” antifungal drugs, which interfere with the sterol fungal agents. metabolism of the infectious agent. Ketoconazole, an (J Fam Pract 1996; 43:127-132) ormal skin flora includes two morpho­ than formerly thought. In one study, children under logically discrete lipophilic yeasts: a age 14 represented nearly 5% of confirmed cases spherical form, Pityrosporum orbicu- of the disease.3 In many of these cases, the face lare, and an ovoid form, Pityrosporum was involved, a rare manifestation of the disease in ovale. Whether these are separate enti­ adults.1 The condition is most prevalent in tropical tiesN or different morphologic forms in the cell and semitropical areas, where up to 40% of some cycle of the same organism remains unclear.: In the populations are affected.
    [Show full text]
  • SLINDA® (DROSPIRENONE 4 Mg) TABLETS
    SLINDA® (DROSPIRENONE 4 mg) TABLETS AUSTRALIAN PRODUCT INFORMATION AUSTRALIAN PRODUCT 4.2 Dose And Method Of INFORMATION Administration SLINDA® (DROSPIRENONE) TABLETS Dose How to take SLINDA 1. NAME OF THE MEDICINE One tablet is to be taken daily for 28 Drospirenone consecutive days; one white active tablet daily during the first 24 days and one green inactive tablet 2. QUALITATIVE daily during the 4 following days. Tablets must be taken every day, at about AND QUANTITATIVE the same time of the day, so that the COMPOSITION interval between two tablets is always 24 hours. Tablets should be taken in White active film-coated tablets: the order shown on the blister. Stickers Each tablet contains 4 mg of marked with the 7 days of the week are drospirenone. provided. The patient should choose the sticker that starts with the day they Green placebo film-coated tablets: begin taking the tablets and stick it on The tablet does not contain active the blister. substances. The first tablet of the treatment should Excipient(s) with known effect: be taken on the first day of menstrual Each white active film-coated tablet bleeding. Thereafter tablet taking contains 17.5 mg of lactose. is continuous. A subsequent pack is started immediately after finishing the Each green placebo film-coated tablet previous pack, without a break in daily contains 55.5 mg of lactose monohydrate. tablet intake. For the full list of excipients, see section How to start SLINDA 6.1 List of Excipients. No preceding hormonal contraceptive use (in the past month) Tablet-taking has to start on day 1 of the 3.
    [Show full text]
  • Desogestrel-Only Pill (Cerazette)
    J Fam Plann Reprod Health Care: first published as 10.1783/147118903101197593 on 1 July 2003. Downloaded from Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit A unit funded by the FFPRHC and supported by the University of Aberdeen and SPCERH to provide guidance on evidence-based practice New Product Review (April 2003) Desogestrel-only Pill (Cerazette) Journal of Family Planning and Reproductive Health Care 2003; 29(3): 162–164 Evidence from a randomised trial has shown that a 75 mg (microgrammes) desogestrel pill inhibits ovulation in 97% of cycles. Thus, on theoretical grounds, we would expect the desogestrel pill to be more effective than existing progestogen- only pills (POPs). However, Pearl indices from clinical trials comparing it to a levonorgestrel POP were not significantly different. Therefore an evidence-based recommendation cannot be made that the desogestrel pill is different from other POPs in terms of efficacy, nor that it is similar to combined oral contraception (COC) in this respect. An evidence-based recommendation can be made that the desogestrel-only pill is similar to other POPs in terms of side effects and acceptability. The desogestrel-only pill is not recommended as an alternative to COC in routine practice, but provides a useful alternative for women who require oestrogen-free contraception. In clinical trials: l Ovulation was inhibited in 97% of cycles at 7 and 12 months after initiation. l The Pearl index was 0.41 per 100 woman-years, which was not significantly different from a levonorgestrel-only pill. However, the trial providing these data was too small to detect a clinically important difference.
    [Show full text]
  • Etats Rapides
    List of European Pharmacopoeia Reference Standards Effective from 2015/12/24 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 ! Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 ! Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 ! Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 ! Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 ! Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 ! Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 ! A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 ! Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 ! Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 ! butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 ! Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate
    [Show full text]